Sign in
UAE-based medtech company BioSapien secured USD 5.5 mn in a pre-series A funding round led by Mena venture capital giant Global Ventures, according to a statement (pdf). The round also saw participation from Dara Holdings.
Where’s the money going? BioSapien will use the funding to launch clinical trials for its flagship product, MediChip, in the UAE, with patient enrolment for colorectal cancer trials set to begin in Abu Dhabi in 2Q 2025. Trials may later be expanded to other cancers, such as pancreatic and lung, as well as non-cancer treatments, like opioids, biologics, and cell and gene therapies, the statement reads.
The fresh capital will also support product development, manufacturing, and talent acquisition.
What BioSapien does: Founded by Khatija Ali (LinekdIn), the company offers a 3D-printed, slow-release drug delivery platform for localized cancer treatment. The platform focuses on keeping drugs concentrated in the tumor microenvironment, reducing required dosages, minimizing systemic side effects, and improving treatment efficiency.
